Surviving the GLP-1 Bellwether Crunch: How Fast Can You Verify the Gastroparesis Timeline?

In a mass tort, a case is only as strong as the timeline you can prove from the records.

The GLP-1 mass tort is moving fast, and the pressure is not about how many leads you have. It is about how quickly you can tell which GLP-1 gastroparesis files show the documented medical timeline the court will expect. When a multidistrict litigation (MDL), the federal process that consolidates similar product-liability cases before one judge, starts pushing toward bellwether trials, weak files stop being harmless. They cost discovery time and money.

Are you carrying intake that no one has screened against the actual medical records? You are not the only firm in that position. Thousands of GLP-1 claims are in the pipeline, and most were signed on a phone call, not a chart review.

The good news: the facts that decide these files are usually already in the records, if someone reads the pharmacy history and the treatment notes and lines up the dates. Let's look at where the GLP-1 litigation stands, and what a fast, court-ready screen checks.

Where the GLP-1 litigation stands in 2026

The federal GLP-1 cases are consolidated in MDL 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, before Judge Karen Marston in the Eastern District of Pennsylvania. The claims allege that GLP-1 receptor agonists such as Ozempic and Wegovy caused gastroparesis and other gastrointestinal injuries. As of mid-2026, the litigation had grown to roughly 3,600 pending cases, the court had largely denied the manufacturers' motion to dismiss in August 2025, and the parties were working through expert and general-causation discovery. No bellwether trial date has been set yet.

Here is why that matters for intake. General causation, whether the science shows GLP-1 drugs can cause gastroparesis, is contested and is the pivotal fight heading into the expert phase. That is a question for the court and the retained experts, not for a records team. What a records team can do is make sure each file documents the facts that a viable claim depends on, before the crunch arrives.

Source Credit: MDL 3094 status per the U.S. Judicial Panel on Multidistrict Litigation and current litigation trackers (Seeger Weiss and mdlupdate.com, mid-2026); case count and motion-to-dismiss ruling as reported for May 2026. Litigation status changes; confirm the current docket before relying on any date.

What the GLP-1 gastroparesis files actually turn on

A GLP-1 gastroparesis file turns on three documented facts and the order they occur in: proof the claimant used the drug, a documented gastroparesis diagnosis, and a timeline showing the drug use came before the injury. Gastroparesis is a condition of delayed gastric emptying, where the stomach empties too slowly, and it can cause severe nausea, vomiting, early fullness and abdominal pain. It is often documented with a gastric emptying study, a test that measures how fast the stomach empties, alongside notes ruling out a physical blockage.

The plaintiff's theory depends on sequence: the drug use has to predate the onset of the injury for the claim to hold together. That is why a medical chronology, a date-ordered and source-linked account of the documented care, is the natural screening tool here. It puts the first documented GLP-1 prescription next to the first documented symptoms and the diagnosis, so the sequence is visible at a glance rather than buried across providers.

A note on the line we hold. LezDo TechMed organizes, cross-references and flags what the records document. Whether those facts establish causation, and whether a given file is viable for the MDL, is the attorney's and the retained experts' call, not ours.

Why the timeline is the whole ballgame

The timeline decides more than the diagnosis, because a real gastroparesis diagnosis does not help the claim if it predates the drug. Picture a claimant who reports Ozempic use and a gastroparesis diagnosis. On the intake call, it looks strong. In the records, the gastroparesis diagnosis is dated two years before the first documented prescription, and the chart shows long-standing type 2 diabetes.

Diabetes is one of the most common documented causes of delayed gastric emptying, so that file carries a confounder and a sequence problem that only the records reveal. Surface it during intake screening and the attorney can make an informed call early. Miss it, and the file may travel deep into discovery before the problem shows up, which is the expensive way to learn it.

Where GLP-1 intake screening breaks down

GLP-1 intake screening breaks down where the volume is highest and the records are thinnest. A firm can hold thousands of signed leads and still not know which ones the medical records support. The common failure points are consistent across mass tort inventories.

• Drug use is self-reported on the intake call, with no pharmacy or prescription record to confirm the drug, the dose, or the dates.
• A gastroparesis diagnosis is claimed, but the records hold no objective study and no note ruling out a physical obstruction.
• Confounders such as diabetes, prior gastrointestinal disease, or other medications that slow gastric emptying are never surfaced.
• Records from key providers, the prescriber and the treating gastroenterologist, are missing from the file.
• The sequence is never checked, so a diagnosis that predates the drug use goes unnoticed.

What a court-ready GLP-1 timeline documents

A court-ready GLP-1 screen documents five things from the records, in order, so the attorney can triage the file quickly.

1. Documented drug use. Pharmacy records, prescriptions and medication lists showing the GLP-1 drug, dose, and start and stop dates.
2. Documented diagnosis. The treating physician's gastroparesis diagnosis, any gastric emptying study, and endoscopy or imaging that addresses obstruction.
3. The sequence. Symptom onset and diagnosis dates placed relative to the first documented GLP-1 use, so the order is clear.
4. Alternative causes, flagged. Diabetes, prior gastrointestinal conditions, and other medications known to delay gastric emptying, surfaced rather than buried.
5. The clinical course. Hospitalizations, treatment, and whether the symptoms persisted, so the file's severity is visible.

Getting there depends on retrieval and organization more than anything clever. Fast sorting and indexing turns a scattered set into a navigable one, and medical record retrieval chases the pharmacy and specialist records that make or break the timeline.

How high-volume firms keep intake moving

High-volume firms keep GLP-1 intake moving by screening every file against the same record-based checklist instead of the intake call. The workflow is practical: retrieve the pharmacy and treatment records, sort and index them, build a short screening chronology that puts drug-use and diagnosis dates side by side, and flag the confounders up front. AI-assisted extraction handles the volume and medical and paramedical reviewers check the detail, with every deliverable passing a three-layer quality-control review.

That is where a records partner earns its place in a mass tort. LezDo TechMed surfaces and organizes the documented facts and flags what is missing or inconsistent. The attorney decides which files to advance, and the retained experts speak to causation.

Questions to ask before you advance a GLP-1 file

• Is there pharmacy or prescription proof of GLP-1 use, with drug, dose and dates?
• Is the gastroparesis diagnosis documented, ideally with a gastric emptying study?
• Does the first documented drug use predate the symptom onset and the diagnosis?
• Is there documented diabetes or another cause of delayed gastric emptying to weigh?
• Are the prescriber and gastroenterology records complete, or is something missing?

Source Credit: LezDo TechMed published service figures (24 to 48 hour sorting and indexing, subject to volume and scope; three-layer quality-control process; 99.8% published company accuracy rate).

The bottom line

In a bellwether crunch, speed without documentation is a liability, not an advantage. The GLP-1 files that hold up will be the ones whose records show the drug use, the diagnosis, and the order between them, with the confounders already flagged. The firms that get there first are not the ones with the most leads. They are the ones who screened the records early, while there was still time to fix a gap or let a weak file go.

Facing a wall of GLP-1 intake before the next MDL deadline? Explore LezDo TechMed's medical record review support for mass tort claimant screening, or start with a free trial and see the timeline on a sample of your own files.